{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:03:39Z","timestamp":1790193819388,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T00:00:00Z","timestamp":1237852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite limited evidence from clinical studies, anticoagulant drugs such as vitamin K antagonists (VKA) (e.g., warfarin or phenprocoumon) are widely used in the background treatment of patients with pulmonary arterial hypertension (PAH). According to current guidelines, they are generally accepted as efficacious drugs, although their efficacy is neither supported by randomised controlled trials, nor formally approved by regulatory agencies for use in the specific PAH indication. The use of these drugs is not without problems, as a paradoxical situation has to be managed in the treatment of this condition. On one hand, thrombosis is one of the key pathophysiologic features of PAH (besides vasoconstriction, proliferation and inflammation). On the other hand, the incidence of bleeding events is increased in PAH patients. This applies particularly to PAH that is related to connective tissue diseases, congenital heart disease and chronic thromboembolic pulmonary hypertension. In patients receiving VKA, caution must be observed in particular when concomitantly using prostanoids or sildenafil. Similarly, VKA doses have to be adjusted according to the labelling when using sitaxentan concomitantly. Regular International Normalized Ratio monitoring contributes to the safety of PAH patients on VKA.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02122.x","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T10:51:01Z","timestamp":1237891861000},"page":"68-73","source":"Crossref","is-referenced-by-count":19,"title":["Bleeding events in pulmonary arterial hypertension"],"prefix":"10.1111","volume":"39","author":[{"given":"C. F.","family":"Opitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035488"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.1_suppl.35S"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.3.841"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02207098"},{"key":"e_1_2_6_7_2","first-page":"1013","article-title":"Systemic sclerosis complicated by diffuse alveolar hemorrhage","volume":"7","author":"Chaer RA","year":"2001","journal-title":"Med Sci Monit"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.45.11.903"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.32.6.767"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(00)87082-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(05)80053-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.1998.7.1099"},{"key":"e_1_2_6_13_2","first-page":"1821","article-title":"Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies","volume":"23","author":"Vazquez\u2010Del Mercado M","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600506"},{"key":"e_1_2_6_15_2","first-page":"66","article-title":"Pulmonary hemorrhage in systemic lupus erythematosus","volume":"29","author":"Gamsu G","year":"1978","journal-title":"J Can Assoc Radiol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003930200027"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0041-87812004000100008"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(05)80022-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(75)90119-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-9-199805010-00008"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001273420407"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.07.022"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.038"},{"key":"e_1_2_6_25_2","first-page":"501","volume-title":"The Pulmonary Circulation","author":"Cohen M","year":"1990"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.3.714"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.70.4.580"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270203"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02966.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(96)00140-4"},{"key":"e_1_2_6_31_2","unstructured":"GSK.Flolan(R) (Epoprostenol Sodium) for Injection. Full prescribing information. Available at:http:\/\/us.gsk.com\/products\/assets\/us_flolan.pdf(accessed on 1 March 2009)."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2674"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.9.1197"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00094302"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008380"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00003"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C398"},{"key":"e_1_2_6_40_2","unstructured":"European Medicines Agency (EMEA). Tracleer(R).Summary of Product Characteristics. Available at:http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/tracleer\/H\u2010401\u2010PI\u2010en.pdf(accessed on 1 March 2009)."},{"key":"e_1_2_6_41_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP)2006. Thelin(R). Public Assessment Report. Summary of Product Characteristics. Available at:http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/thelin\/thelin.htm(accessed on 1 March 2009)"},{"key":"e_1_2_6_42_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP). Thelin European Public Assessment Report Scientific Discussion pp 25\u201026. Available at:http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/thelin\/thelin.htm(last accessed on 1 March 2009)."},{"key":"e_1_2_6_43_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP)2006. Committee for Proprietary Medicinal Products (CPMP). Volibris(R). European Public Assessment Report. Summary of Product Characteristics. April 2008. Accessed on 22 December 2008."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_2_6_45_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP). Volibris\u00ae Public Assessment Report. Summary of Product Characteristics. Available at:http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/volibris\/volibris.htm(accessed on 4 December 2008)."},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.95.10.528"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.95.8.402"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0618-z"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/02688690120072513"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170250"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04077.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05876.x"},{"key":"e_1_2_6_53_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP). Revatio(R). European Public Assessment Report. Scientific Discussion page 13f. Available at:http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Revatio\/30895705en6.pdf(accessed on 1 March 2009)."},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00138706"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03075.x"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01180-X"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc0502.103329"},{"key":"e_1_2_6_59_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archinte.1992.00400170079015","article-title":"Effects of long\u2010term anticoagulant therapy in subgroups after acute myocardial infarction","volume":"152","author":"Smith P","year":"1992","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09409-6"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02122.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02122.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:50:11Z","timestamp":1694400611000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02122.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,24]]},"references-count":59,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02122.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02122.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,24]]}}}